2 days ago
1
Dr. Reddy’s Laboratories has launched successful India oral semaglutide biosimilar successful tablet form.
The merchandise volition beryllium disposable nether Obeda brand, the aforesaid sanction nether which the Hyderabad-based generic drugmaker had rolled retired the generic mentation of the benignant 2 diabetes cause successful injection signifier connected March 21.
The motorboat successful tablet signifier comes days aft it introduced its generic Semaglutide injection successful Canada, “further establishing the presumption arsenic a full‑stack subordinate successful GLP‑1 therapies,” Dr. Reddy’s said successful a merchandise connected Wednesday (May 20, 2026). A prescription-based drug, the tablets are disposable successful 3 mg, 7 mg and 14 mg strengths. It is priced astatine ₹99, ₹135, and ₹225 per tablet for the 3 mg, 7 mg, and 14 mg doses, respectively, the institution said.
“With this launch, we are broadening our GLP‑1 portfolio. As the merchandise is developed and formulated in-house, we are committed to reliable proviso and accordant prime for patients successful India,” CEO-Global Generics M.V. Ramana said.
Semaglutide is the progressive constituent successful Danish large Novo Nordisk’s blockbuster diabetes and value nonaccomplishment drugs, Wegovy and Ozempic. Soon aft the patent connected Semaglutide expired, a clutch of drugmakers successful India, including Dr. Reddy’s rolled retired their generic versions of the product, triggering a terms warfare and eyeing a pastry of the market.
Dr. Reddy’s said Obeda (semaglutide tablets) is formulated utilizing recombinant DNA (rDNA) root of semaglutide progressive pharmaceutical ingredient. It had obtained support for its oral semaglutide biosimilar from the CDSCO pursuing a reappraisal of a Phase III objective survey enrolling 288 participants with benignant 2 diabetes mellitus conducted successful India, which demonstrated non-inferior efficacy and a information illustration comparable to the innovator oral drug.
